Ronald Rubin, MD
Psychiatry · Kenosha, WINPI 1598834574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,538 and has fallen 80.6% since, to $298 in 2025. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $52.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$881
- AbbVie$740
- Lundbeck LLC$496
- Otsuka America Pharmaceutical, Inc.$442
- Alkermes, Inc.$434
- plus $1K from 10 others
What the payments were for
- Food & beverage$5,20396%
- Education$2034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $1,103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $881 |
| AbbVie(2 entities) | 17 | $740 |
| Lundbeck LLC | 18 | $496 |
| Otsuka America Pharmaceutical, Inc. | 6 | $442 |
| Alkermes, Inc. | 9 | $434 |
| Sunovion Pharmaceuticals Inc. | 7 | $283 |
| USWM, LLC | 2 | $242 |
| Neurocrine Biosciences, Inc. | 4 | $185 |
| Indivior Inc. | 8 | $142 |
| Almatica Pharma LLC | 8 | $134 |
| Corium, LLC | 1 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $110 |
| Johnson & Johnson | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,000
- CAPLYTA$691
- VRAYLAR$567
- LYBALVI$420
- UZEDY$368
- Austedo XR$250
- ARISTADA INITIO$250
- AUSTEDO$248
- LUCEMYRA$242
- LATUDA$231
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- REXULTI$125
- INGREZZA$124
- Azstarys$122
- Fanapt$110
How this compares
$5,405 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $248,377 |
| Invega SustennaPaliperidone Palmitate | 89 | $245,873 |
| VraylarCariprazine Hcl | 124 | $161,253 |
| PerserisRisperidone | 49 | $141,607 |
| AustedoDeutetrabenazine | 17 | $112,576 |
| Abilify MaintenaAripiprazole | 36 | $87,559 |
| Austedo XrDeutetrabenazine | 14 | $85,499 |
| CaplytaLumateperone Tosylate | 52 | $81,974 |
| RexultiBrexpiprazole | 40 | $64,755 |
| Lurasidone Hcl | 240 | $52,819 |
| UzedyRisperidone | 15 | $42,574 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $41,236 |
| Aripiprazole | 293 | $35,473 |
| Risperidone ErRisperidone Microspheres | 24 | $23,548 |
| TrintellixVortioxetine Hydrobromide | 29 | $14,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $185 | $248,37729 claims |
| Johnson & JohnsonInvega Sustenna | $51 | $245,87389 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $1,103 | $240,64946 claims |
| AbbVieVraylar | $740 | $161,253124 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $442 | $152,31476 claims |
| Indivior Inc.Perseris | $142 | $141,60749 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $881 | $81,97452 claims |
| Alkermes, Inc.Lybalvi | $434 | $41,23624 claims |
| Almatica Pharma LLCSertraline Hcl | $134 | $1,662226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Kenosha
- Shalini VarmaKenosha$12K
- Scott WienerGreenfield$1.4M
- Joseph BergsRacine$346K
- Royle EenigenburgJuneau$344K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Sobia Kirmani MoeMadison$104K
- Jacob BehrensMilwaukee$94K
- Ned KalinMadison$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.